Porcine reproductive and respiratory syndrome virus (PRRSV) continues to be a major problem in the pork industry worldwide. The limitations of current PRRSV vaccines require the development of a new generation of vaccines. One of the key steps in future vaccine development is to include markers for diagnostic differentiation of vaccinated animals from those naturally infected with wild-type virus. Using a cDNA infectious clone of type 1 PRRSV, this study constructed a recombinant green fluorescent protein (GFP)-tagged PRRSV containing a deletion of an immunogenic epitope, ES4, in the nsp2 region. In a nursery pig disease model, the recombinant virus was attenuated with a lower level of viraemia in comparison with that of the parental virus. To complement the marker identification, GFP and ES4 epitope-based ELISAs were developed. Pigs immunized with the recombinant virus lacked antibodies directed against the corresponding deleted epitope, but generated a high-level antibody response to GFP by 14 days post-infection. These results demonstrated that this recombinant marker virus, in conjunction with the diagnostic tests, enables serological differentiation between marker virus-infected animals and those infected with the wild-type virus. This rationally designed marker virus will provide a basis for further development of PRRSV marker vaccines to assist with the control of PRRS.
INTRODUCTION
Porcine reproductive and respiratory syndrome (PRRS) is the most economically significant disease of swine worldwide. It is characterized by late-term reproductive failure in sows and severe pneumonia in neonatal pigs. Since its emergence in domestic swine in the 1980s, PRRS has resulted in immense economic losses to the swine industry, with recent costs in the USA of at least US$600 million annually (Neumann et al., 2005) . The aetiological agent of PRRS is a small, enveloped virus (PRRSV) containing a single, positive-stranded RNA genome. PRRSV belongs to the family Arteriviridae, which includes equine arteritis virus (EAV), lactate dehydrogenase-elevating virus and simian hemorrhagic fever virus (Snijder & Meulenberg, 1998) . Nucleotide sequence comparisons have shown that PRRSV can be divided into distinct European (type 1) and North American (type 2) genotypes (Allende et al., 1999; Nelsen et al., 1999) .
The PRRSV genome is about 15 kb in length and contains nine open reading frames (ORFs). The 39 end of the genome encodes four membrane-associated glycoproteins (GP2, GP3, GP4 and GP5, encoded by subgenomic mRNAs 2a, 3, 4 and 5), two unglycosylated membrane proteins (E and M; encoded by subgenomic mRNAs 2b and 6) and a nucleocapsid protein (N; encoded by subgenomic mRNA 7) Mounir et al., 1995; Bautista et al., 1996; Mardassi et al., 1996; Meng et al., 1996; Meulenberg & Petersen-den Besten, 1996; Wu et al., 2001 Wu et al., , 2005 . The replicase-associated genes, ORF1a and ORF1b, situated at the 59 end of the genome, represent almost 75 % of the viral genome. The ORF1ab-encoded polyprotein pp1ab is predicted to be cleaved at 12 sites to form 13 products: nsp1a, nsp1b and nsp2 to nsp12 (den Boon et al., 1995; Snijder & Meulenberg, 1998; Allende et al., 1999; Nelsen et al., 1999) . Based on the study of EAV, the nsp2 plays a crucial role in viral replication. The nsp2 protein contains a cysteine protease domain residing in the N terminus. This domain induces nsp2/3 cleavage and also functions as a co-factor with nsp4 serine protease to process the other cleavage products (Snijder et al., 1994 Wassenaar et al., 1997) . In addition to their function in viral replication, a recent study showed that cysteine proteases of EAV and PRRSV nsp2 belong to the ovarian tumour (OTU) protease superfamily. The OTU protease is capable of deconjugating both ubiquitin and ISG15 from cellular proteins, which inhibits the Ub-and ISG15-dependent innate immune response (Frias-Staheli et al., 2007) .
Modified live-virus vaccines against PRRSV are currently available for the reduction of clinical disease associated with PRRSV (Osorio et al., 1998; Mengeling et al., 1999; Labarque et al., 2004; Martelli et al., 2007) . However, vaccinated pigs cannot be distinguished serologically from pigs that have recovered from a natural infection. A genetically marked vaccine would allow the differentiation of vaccinated and naturally infected pigs, and would be valuable for PRRS control and eradication programmes. Modified live-virus vaccines containing genetic markers have been developed for other RNA and DNA viruses by inserting a foreign antigen to create a positive marker or by deleting an immunogenic protein (epitope) to create a negative marker. The antibody responses to the foreign antigen or viral protein (epitope) are used to differentiate vaccinated animals from naturally infected animals (Moormann et al., 1990; Kaashoek et al., 1994; van Oirschot et al., 1996; van Oirschot, 1999; Walsh et al., 2000a, b; Widjojoatmodjo et al., 2000; Mebatsion et al., 2002; Castillo-Olivares et al., 2003; Dong & Chen, 2007) . Previous studies have shown that the PRRSV nsp2 protein is an excellent candidate site for marker modification (Fang et al., 2006; Kim et al., 2007; de Lima et al., 2008) . The most important property of nsp2 related to marker engineering is the ability of nsp2 to tolerate large deletions and insertions. Nucleotide sequence insertions/deletions have been reported within the central region of the protein (Shen et al., 2000; Gao et al., 2004; Han et al., 2007; Tian et al., 2007; Ran et al., 2008) . In previous studies, we identified several unique deletions in the nsp2 region of US type 1 PRRSV isolates (Fang et al., , 2007 Ropp et al., 2004) . Another property related to marker engineering is the presence of several immunodominant epitopes in this region. Oleksiewicz et al. (2001) identified six linear B-cell epitope sites (ES) in the nsp2 region of a Danish type 1 virus (ES2-ES7). In type 2 PRRSV, de Lima et al. (2006) found that nsp2 contained the highest frequency of immunodominant epitopes when compared with structural proteins.
In this study, we focused on developing marker modifications in the nsp2 region of a US type 1 PRRSV infectious clone (Fang et al., 2006) . A highly immunogenic epitope, ES4, located in the nsp2 region (aa 736-790 of pp1a) was deleted and replaced with the green fluorescent protein (GFP) gene (at aa 733/734 of pp1a) using reverse genetics.
The in vitro replication features and in vivo biological properties of the resulting recombinant virus were characterized to determine its potential use as a marker vaccine against PRRSV infection. GFP antigen and ES4 peptide antigen-based ELISAs were tested to determine their sensitivity and specificity as companion diagnostic assays for marker detection and differentiation.
METHODS
Cells and viruses. Baby hamster kidney cells (BHK-21/C13; ATCC) and MARC-145 cells were cultured as described previously (Fang et al., 2006) . BHK-21 cells were used for initial transfection and recovery of virus from in vitro-transcribed RNA. MARC-145 cells were used for virus rescue and subsequent experiments. The GFP/DES4 marker virus was constructed from a US type 1 PRRSV full-length cDNA infectious clone, pSD01-08 (Fang et al., 2006) . The second passage of the MARC-145 cell-recovered parental and marker viruses was used for in vitro and in vivo experiments. As the marker virus had a lower viral titre than the parental virus, the marker virus was concentrated for in vivo experiments using the sucrose cushion method as described previously (Wu et al., 2001; Yuan et al., 2004) . The concentrated virus pellets were resuspended in cell-culture medium, and viral titres were determined by titration on MARC-145 cells and quantified as 50 % tissue culture infective dose (TCID 50 ) ml
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The US type 1 strain SD03-15 was used to challenge pigs at 42 days post-infection (p.i.). SD03-15 was isolated from clinical samples submitted to our diagnostic laboratory in 2003. Our previous studies showed that SD03-15 possesses 90.1 (nsp2) or 94.5 % (GP5) amino acid identity to SD01-08 (Fang et al., , 2007 . In field reports, pigs infected with SD03-15 experienced a pre-weaning mortality of 80-90 % for a 3 week period. Decreased performance continued through the finisher phase. In the adult sow population, there was a mild abortion storm, compared with previous US PRRSV outbreaks.
GFP/DES4 marker virus construction. In a previous study (Fang et al., 2006) , we constructed the pSD01-08-GFP plasmid with the GFP gene inserted into the nsp2 region (at nt 2420/2421) of the SD01-08 virus genome. In this study, the B-cell epitope ES4, which is located downstream of GFP (at nt 2427-2591 of the SD01-08 viral genome), was deleted by overlapping extension PCR techniques (Hayashi et al., 1994) using primer pairs DES4F/E3448R and E1895F/DES4R (see Supplementary Table S1 , available in JGV Online). The PCR product was digested with RsrII and EcoRV restriction enzymes and ligated into the pSD01-08-GFP plasmid, which was digested with the same restriction enzymes. The resulting plasmid construct was designated pSD01-08-GFP/DES4.
In vitro characterization of GFP/DES4 marker virus. The plasmids pSD01-08-GFP/DES4 and pSD01-08 were transcribed in vitro and transfected into BHK-21 cells as described previously (Fang et al., 2006) . To rescue the virus, cell culture supernatant obtained at 48 h post-transfection was passaged on MARC-145 cells. Rescue of infectious virus was observed under fluorescent microscopy and further confirmed by an indirect immunofluorescent assay (IFA) using PRRSV-specific monoclonal antibody (mAb) SDOW17 (Nelson et al., 1993) . The growth kinetics of marker and parental viruses were examined by infecting MARC-145 cells with viruses at an m.o.i. of 0.1. Infected cells were collected at 0, 6, 12, 24, 36, 48, 60 and 72 h p.i., and viral titres were determined by IFA on MARC-145 cells and quantified as fluorescent focus units (f.f.u.) ml
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. Plaque morphology between the marker virus and parental virus was compared by plaque assay on MARC-145 cells as described previously (Fang et al., 2006) .
Genetic marker development in nsp2 region of PRRSV Animal study. Eighteen 4-week-old pigs were purchased from a PRRSV-free herd. The animals were randomly separated into three groups (n56 per group) and housed under BL2 isolation conditions with an acclimation period of 7 days before starting experimental inoculations. Group 1 pigs were infected with GFP/DES4 marker virus, group 2 pigs were infected with parental SD01-08 virus as a positive control and group 3 pigs were mock-infected with the cellculture medium. Group 1 and group 2 pigs were inoculated through both intranasal and intramuscular sites with 1610 6 TCID 50 ml 21 of the virus (1 ml at each site). On day 42 p.i., group 1 and group 2 pigs were challenged with SD03-15 virus. Three pigs from group 3 were also challenged with SD03-15 virus, whilst the remaining three pigs were kept as mock-infected controls. Blood samples were obtained once a week from all pigs. Pigs were euthanized at 21 days postchallenge.
Virus isolation. Serum samples taken at 7, 14, 21 and 28 days p.i. were used for virus isolation as described previously (Wasilk et al., 2004) . The presence of virus was confirmed by IFA with the PRRSVspecific mAb SDOW17 (Nelson et al., 1993) .
DNA sequencing. To determine the stability of the GFP insertion and ES4 epitope deletion, viral RNA was extracted from the initial in vitro-recovered virus (passage 10 on MARC-145 cells) or from the serum-isolated virus using a QIAamp Viral RNA Mini kit (Qiagen). RT-PCR was performed using a previously described method . The PCR product was purified using a QIAquick PCR purification kit (Qiagen) and cloned into the pCR2.1 plasmid vector (Invitrogen). Twenty individual bacterial colonies were selected for each clone. Plasmid DNA was extracted using a QIAprep Spin Miniprep kit (Qiagen), and the sequence was determined at the Iowa State University sequencing facility (Ames, IA, USA). Primer pair nsp2-2144F/nsp2-2694R (see Supplementary Table S1 ) was used for RT-PCR and sequencing, and amplified nt 2144-2694 of the SD01-08 genome containing the GFP insertion and ES4 deletion.
Quantification of viral load. For the detection of viral RNA and determination of viral load, serum and tissue samples were examined using a real-time, quantitative PCR (Tetracore VetAlert PRRS; Wasilk et al., 2004) , which is performed routinely at the South Dakota Animal Disease Research and Diagnostic Laboratory (SDSU-ADRDL).
Determination of humoral immunity. All serum samples were evaluated for anti-PRRSV antibodies using an IDEXX HerdChek PRRS ELISA. This test is also performed routinely at SDSU-ADRDL under strict quality assurance guidelines.
ES4 and GFP antigen expression. The ES4 antigen was expressed as tandem-repeat ES4 epitopes using a modified method described previously (Sun et al., 2004) . Briefly, three copies of the ES4 epitope (aa 736-790 of pp1a of SD01-08) were constructed in the protein expression vector pET-28a (+) (Novagen). A flexible peptide linker, GGGGS, was added between the epitopes to help display the epitopes. There were two forward primers. Forward primer 1, pET-ES4F1, contained a BglII restriction site, but without a linker sequence, whereas forward primer 2, pET-ES4F2, contained a BglII restriction site and the linker sequence. The ES4 gene fragment was first amplified with forward primer 1 and reverse primer pET-ES4R. The PCR product was digested with BglII and HindIII, and then cloned into pET-28a that had been digested with BamHI and HindIII. This clone was designated pET-28a-ES4 (+1). The second copy of ES4 was PCR amplified by forward primer 2 and reverse primer pET-ES4R. The PCR product was digested with BglII and HindIII, and then cloned into pET-28a-ES4 (+1) that had been digested with BamHI and HindIII. The third copy of ES4 was inserted using the same strategy as the second copy. The final construct was designated pET28a-ES4 (+3). The GFP gene was amplified from plasmid pEGFP-N1 (Clontech) with primer pair pET-EGFP-F/pET-EGFP-R. The PCR product was digested with BamHI and HindIII and ligated to pET-28a vector that had been digested with the same enzymes. Recombinant proteins were expressed in Escherichia coli BL21(DE3) to produce a fusion protein with six histidine residues at the N terminus. Proteins were purified by nickel-affinity chromatography and analysed by SDS-PAGE as described previously by us (Ferrin et al., 2004) .
ES4 epitope and GFP antigen-based ELISA. ELISAs were performed using Immulon II HB 96-well microtitre plates (Thermo Labsystems). The recombinant protein was diluted in coating buffer (15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6), and the plates were coated with 100 ml of the diluted antigen in columns 1, 3, 5, 7, 9 and 11. Columns 2, 4, 6, 8, 10 and 12 were treated with 100 ml coating buffer as a background control. Plates were incubated at 37 uC for 1 h, and excess protein-binding sites were then blocked with 10 % skimmed milk in PBST buffer (16 PBS with 0.05 % Tween 20) at 4 uC overnight. The test sera were applied at 1 : 50 dilutions in PBST buffer with 5 % skimmed milk. After 1 h incubation at 37 uC, plates were washed with PBS, and horseradish peroxidase-conjugated goat anti-swine IgG (Kirkegaard & Perry Laboratories) was added to detect any serum antibodies that were bound to the antigen on the plates. Plates were incubated at 37 uC for another hour and washed, and the peroxidase substrate ABTS (Kirkegaard & Perry Laboratories) was added for colour development. Colour development was quantified by reading at 405 nm in an EL800 microplate reader (BioTek Instruments) controlled by xChek software (IDEXX Laboratories).
Serum samples from other type 1 and type 2 PRRSV-infected animals. To determine the reactivity of the ES4 epitope with various strains of PRRSV, serum samples were obtained from a group of experimental pigs infected with four different representative strains of type 1 virus: SD01-07, SD01-08, SD02-11 and SD03-15 (Lawson et al., 2005) . The SD01-07 and SD01-08 isolates were obtained from herds showing no clinical disease, whilst SD02-11 and SD03-15 were from herds with substantial morbidity and mortality in young pigs. These four isolates also group into different branches of the phylogenetic tree developed for type 1 PRRSV isolates of US origin (Fang et al., 2007) . Serum samples for type 2 PRRSV were from experimental pigs infected with VR2332.
Statistical analysis. Statistical analysis was performed using GraphPad InStat version 3.06 (GraphPad Software). Comparison of virus load in serum samples was performed by one-way analysis of variance with Tukey's multiple comparison tests to determine mean significance. Differences between groups of pigs at different times post-inoculation were considered statistically significant at P¡0.05 for all analyses.
RESULTS
In vitro characterization of GFP/DES4 marker virus
In a previous study, we attempted to engineer a positive marker, the GFP gene, into the nsp2 region of a US type 1 PRRSV infectious clone (Fang et al., 2006) . Unfortunately, the GFP gene was not stable. The N-terminal 159 aa were lost in a subpopulation of the virus by the seventh passage in cell culture. In order to obtain a potential negativemarker vaccine virus, in this study, the B-cell epitope ES4 that is located downstream of the GFP was deleted using our reverse genetics system, resulting in plasmid pSD01-08-GFP/DES4 (Fig. 1a) . Direct transfection of this plasmid DNA into BHK-21 cells initiated a full cycle of virus replication. When the cell-culture supernatants from BHK-21 cells were passaged in MARC-145 cells, infectious progeny virus was recovered, and the resulting virus was designated GFP/DES4 marker virus. The parental virus, SD01-08, was generated in parallel from the pSD01-08 cDNA clone. Passage two of the viruses from MARC-145 cells was used for in vitro and in vivo characterization.
The growth kinetics study showed that the GFP/DES4 marker virus replicated with slightly slower kinetics, reaching maximal titre several hours later than the parental virus, SD01-08. The peak viral titre of the marker virus (3.34610 4 f.f.u. ml
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) was approximately 2 logs lower than that of the parental virus (2.56610 6 f.f.u. ml 21 ) (Fig. 1b) . Viral plaques formed by the GFP/DES4 marker virus were reduced in size (Fig. 1c) , suggesting a negative effect of the GFP insertion/ES4 deletion on the rate of cellto-cell spread during infection.
The in vitro stability of the GFP insertion and ES4 deletion in the recombinant virus was followed for 10 serial passages in MARC-145 cells. The GFP/DES4 region of passage 10 marker virus was amplified by RT-PCR, and the PCR product was subsequently cloned in plasmid pCR2.1. A total of 20 clones was sequenced. Interestingly, unlike the previous SD01-08-GFP virus (Fang et al., 2006) , the GFP remained intact as a full-length gene and the ES4 deletion was still present. This result suggested that deletion of the ES4 epitope region improved the stability of the inserted foreign gene, GFP. However, mutations were identified in the GFP gene region. In nine sequences, a C289T nucleotide mutation was consistently identified, which caused the amino acid mutation of arginine (R) to cysteine (C) at position 97 of the GFP protein (Fig. 2a) . Within these nine sequences that contained the amino acid R97C . (c) Plaque morphology of GFP/DES4 marker virus and parental virus. Confluent cell-culture monolayers were infected with each virus at an m.o.i. of 0.1. After 2 h infection, the cell-culture supernatant was removed and an agar overlay was applied. Plaques were detected after 5 days at 37 6C by staining with 0.1 % crystal violet.
mutation, other random mutations were also identified. In six of the sequences, a C144T nucleotide mutation was identified, but this was a silent change and did not result in an amino acid change. Three of the sequences contained a nucleotide mutation that caused an amino acid mutation: C41T (PAL), A323G (KAR) and A511G (NAD). The amino acid R97C mutation is the same mutation identified by Kim et al. (2007) when they inserted GFP into the nsp2 region of a North American type 2 PRRSV. Kim et al. (2007) suggested that the R97C mutation may interfere with the GFP chromophore formation or function. In cell culture, we detected a population of infected cells that lost the GFP-associated fluorescence for passage 10 of the marker virus (Fig. 2b) . To verify that the R97C mutation was responsible for the loss of GFP fluorescence, we performed reverse genetics to mutate aa R97 to C in GFP using the original pSD01-08-GFP/DES4 plasmid. The recombinant virus recovered from cell culture showed no fluorescence by fluorescent microscopy, but the virus was detected by IFA using mAb SDOW17 (Fig. 2c) . This result confirmed that the R97C amino acid mutation caused the loss of GFP fluorescence.
In vivo characterization of GFP/DES4 marker virus
The in vivo characteristics of GFP/DES4 marker virus were studied in a nursery pig disease model. Groups 1-3 of 4-week-old PRRSV-negative pigs (n56) were initially inoculated with GFP/DES4 marker virus or parental SD01-08, or were mock infected, respectively.
To determine whether the GFP/DES4 marker virus replicated in vivo, the duration and peak of viraemia were determined by real-time PCR. Viral RNA was detected from 7 to 42 days p.i. Serum samples from 7 to 28 days p.i. were used for virus isolation in MARC-145 cells. Viruses were recovered from the serum samples collected on days 7, 14 and 21 p.i. These results indicated active replication of the marker virus in pigs. However, in comparison with group 2 pigs infected with parental virus (mean peak viral titre55.9610 7 copies ml 21 ), pigs that were infected with the GFP/DES4 marker virus had a lower peak viral load (mean peak viral titre52.08610 5 copies ml
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, Fig. 3a ).
The PRRSV-specific antibody response was monitored by a commercially available ELISA kit (IDEXX HerdChek PRRS 2XR ELISA; IDEXX Laboratories). By day 14 p.i., all of the pigs in the infected groups had seroconverted. Although the GFP/DES4 marker virus replicated at a lower titre in animals compared with the parental virus, the antibody responses reached similar levels after 21 days p.i. as measured by IDEXX ELISA (Fig. 3b) .
To determine the stability of the GFP/DES4 marker in animals, serum samples from 7 to 28 days p.i. were used for virus isolation in MARC-145 cells. Virus was recovered from serum samples collected on days 7, 14 and 21 p.i., but no virus was isolated from the serum samples collected from 28 days p.i. In cell culture, we observed a small population of infected cells showing weak GFP fluorescence with virus isolated at 7 and 14 days p.i., but no GFP fluorescence was observed in cells infected with the virus isolated from 21 days p.i. However, immunofluorescent staining using N protein-specific mAb SDOW17 confirmed the presence of a large population of virus, similar to that observed in the in vitro study (Fig. 2b) . The stability of the GFP insertion/DES4 deletion was determined by sequencing the corresponding regions. The results confirmed the presence of the ES4 deletion, and the GFP gene remained intact as a full-length gene.
However, sequencing results revealed two point mutations that were located at nt 144 (CAT) and 289 (CAT) of the GFP gene. The nt 144 mutation was silent, but the nt 289 mutation caused amino acid mutation of R to C at position 97 of the GFP protein, which was consistent with our in vitro sequencing analysis (Fig. 2a) . Interestingly, there was still a small population of the non-mutated GFP gene detected in the virus isolated from days 7 and 14 p.i. For each day p.i., we sequenced viruses isolated from three pigs, and sequencing was performed using both forward and reverse primers, resulting in a total of six sequences for each day analysed. For the viruses isolated at 7 days p.i., one out of six sequences was found to have no mutation at aa 97, whilst the other five sequences were determined to contain the R97C mutation. For the viruses isolated at 14 days p.i., two out of six sequences had no mutations, and these two sequences were from two different pigs. The other four sequences were also found to contain the R97C mutation. All of the sequences generated from virus from 21 days p.i. contained the R97C mutation. These data were consistent with the results from our in vitro experiments that the loss of GFP fluorescence is due to the R97C mutation. The presence of a small subpopulation of the non-mutated GFP would account for the weakly fluorescing cells observed in cell culture.
GFP antigen and ES4 epitope-based ELISA to differentiate marker virus-vaccinated animals from those infected with wild-type virus
In this study, we constructed two markers in the nsp2 region of the virus, an ES4 deletion (negative marker) and a GFP insertion (positive marker). The negative marker and associated assay allow serological identification of animals infected with wild-type virus and their differentiation from vaccinated and non-infected animals. The positive marker and associated assay allow detection of the vaccinated animals, but by themselves do not allow the identification of vaccinated animals that have subsequently become infected by wild-type virus. The inclusion of both negative and positive markers should enable detection of either the vaccine or wild-type strains of the virus in situations with mixed vaccination/wild-type virus infection. Therefore, to assess the differentiation ability of the GFP/DES4 marker virus in possible field conditions where vaccinated animals have subsequently become infected by a wild-type PRRSV, we challenged pigs at 42 days p.i. with a genetically different strain, SD03-15. We developed both GFP and ES4 epitopebased ELISA assays for marker detection. Both GFP and ES4 epitopes were expressed as soluble recombinant proteins. We evaluated these two ELISA tests for detection of the specific antibodies. As expected, the infection of group 1 pigs with GFP/DES4 marker virus did not induce a detectable antibody response against the deleted ES4 epitope between 0 and 42 days p.i. (Fig. 4a ), but induced a strong antibody response against the GFP antigen, starting from 14 days p.i. and continuing for the duration of the study to 62 days p.i. (Fig. 4b) . In contrast, in group 2 pigs that were infected with parental virus, antibody specific to ES4 recombinant protein could be detected at 21 days p.i. and remained detectable up to 62 days p.i. (Fig. 4a) , whilst no specific antibody response was detected against GFP antigen (Fig. 4b) . After challenge with SD03-15, group 1 pigs showed a detectable antibody response to the ES4 epitope (negative marker) 1 week after challenge, as SD03-15 virus contains the ES4 epitope (Fig. 4a) . At the same time, robust antibody responses to GFP antigen were detected. No specific antibody response was detected using GFP and ES4 epitope-based ELISAs for serum samples from the three negative-control pigs (Fig. 4a,  b) . For the three pigs that were mock infected and subsequently challenged with SD03-15, ES4-specific antibody responses were detected at 56 days p.i. (2 weeks after SD03-15 challenge). As summarized in Table 1 , our results showed that marker virus-vaccinated pigs could be identified by a GFP-positive ELISA result, wild-type virus exposed pigs could be identified by an ES4-positive ELISA result and dual-exposure pigs (vaccinated and wild-type virus exposure) could be identified by both GFP-and ES4-positive ELISAs. These data demonstrated that our GFP and ES4 double-marked virus and the companion ELISA assays correctly identified the vaccination/infection status of the animals. A basic requirement for the negative marker is that the antigenic region should be able to react with a broad array of field viruses. To ensure that the ES4 epitope was reactive in various viral strains, we used serum samples from pigs infected with each of the four representative strains of the US type 1 virus, SD01-07, SD01-08, SD02-11 and SD03-15. As shown in Fig. 4(c) , the ES4 epitope reacted with antisera from all of the pigs infected with these four viral strains. The antibody response was detected by 14 days p.i. and was detectable for at least 62 days p.i. However, further testing of serum samples from a group of experimental pigs infected with type 2 prototypic strain VR2332 showed no reactivity with the ES4 epitope on the ELISA (data not shown). Therefore, another serological test will be required to differentiate animals infected with type 1 viruses from those infected with type 2 viruses.
DISCUSSION
Improved protection through immunization requires a new generation of PRRSV vaccines. One of the key steps in future vaccine development is to include markers for the diagnostic differentiation of vaccinated animals from those that are naturally infected with wild-type virus. Marker vaccines are important in programmes aimed at controlling or eradicating virus infections in livestock animals, as well as in companion animals Babiuk et al., , 2002 van Oirschot, 2001) . Herpesvirus marker vaccines were among the first to be shown to be effective in the field (Bosch et al., 1996; van Oirschot et al., 1996) , followed by various genetically modified RNA viruses, such as classical swine fever virus (Widjojoatmodjo et al., 2000; van Gennip et al., 2002; Floegel-Niesmann, 2003) and Rinderpest virus (Walsh et al., 2000a, b; Barrett et al., 2003) . With a PRRSV elimination programme, the international trade in pigs and pork will require a marker vaccine in the future. Furthermore, as the world is progressively moving towards the elimination of PRRSV, serosurveillance is an essential tool to verify disease status. The currently available conventional vaccines are unable to allow differentiation between wild-type infection and vaccination. Thus, serosurveillance is impossible in the face of ongoing vaccination or for several months after vaccination has ceased. Clearly, a marked vaccine would be of great benefit. In this study, we constructed two genetic markers in the nsp2 region of the virus, a positive-marker GFP insertion and a negative-marker ES4 epitope deletion. The antibody response to the positive marker can serve as an indicator of acquired immunity after vaccination and of vaccine compliance. In our case, one potential advantage of the GFP-tagged vaccine virus would be to follow the vaccine strain in trial studies before its licensing. However, in disease control/eradication programmes, it is essential to include a negative marker because, if only the positive marker was present, animals dually exposed to wild-type virus and vaccine could not be differentiated from those animals that were vaccinated only. Our results show that it is possible to develop such 'double-marker' PRRSV vaccines, so that vaccinated pigs can be differentiated from those exposed to wild-type virus or those with mixed infections (vaccine virus and wild-type virus exposure).
Marker vaccines are only useful if suitable tests (companion diagnostic tests) are available to monitor the vaccination levels and to follow the temporal course of the infection. Our results showed that the GFP antigenbased ELISA detected a high level of anti-GFP response in the group of pigs infected with the marker virus. The ES4 epitope-based ELISA also detected a high level of antibody response in the group of pigs infected with the parental virus, but this appeared to develop slower than that of the anti-GFP response. A high-level, robust anti-GFP response could be detected by 14 days p.i. in marker virus-infected pigs, whilst the anti-ES4 antibody response was detected by 21 days p.i. and reached higher levels by 28 days p.i. in pigs infected with wild-type virus. The ES4 epitope was chosen as the negative marker based on its effect on viral replication, antigenicity and sequence conservation. Among the six B-cell epitopes identified within the nsp2 region of type 1 virus (Oleksiewicz et al., 2001) , only ES3, ES4 and ES7 deletion generated viable viruses. We developed ES3-, ES4-and ES7-based ELISAs, and the results showed that the ES4-based ELISA had the highest sensitivity and specificity (data not shown). Sequence analysis also showed that the ES4 epitope possesses the (Hopp & Woods, 1981) . Analysis of the currently available nsp2 amino acid sequences of type 1 PRRSV (Meulenberg et al., 1993; Ropp et al., 2004; Fang et al., 2007) showed that this region possesses 63.6-100 % amino acid sequence identity within the type 1 genotype, and the ES4 epitope region, aa 736-790, actually contains seven small B-cell epitopes (PepTool; BioTools). The epitopes aa 745-754 and 768-780 are well conserved within the type 1 genotype. Our ES4 ELISA data were consistent with the protein sequence analysis, showing that the ES4 epitope can react with serum samples from animals infected with four representative field strains of type 1 PRRSV. To ensure that the ES4 epitope could be used as a marker candidate for all type 1 PRRSV strains in the field, more extensive analysis is required to screen serum samples from European regions where type 1 strains are prevalent. In addition, one drawback of using the ES4 epitope ELISA is that the ES4 epitope is not conserved among genotypes. The ES4 epitope did not react with serum samples from animals infected with type 2 isolates. A comparison of the identified B-cell epitopes in the nsp2 region (Oleksiewicz et al., 2001; de Lima et al., 2006) revealed that none of the epitopes identified was conserved between type 1 and type 2 isolates. Therefore, another diagnostic assay is required to differentiate pigs vaccinated with the ES4 epitope deletion mutant from those pigs infected with type 2 field strains.
Our results suggest that the ES4 epitope in the nsp2 region is non-essential for PRRSV replication but may play an important role in viral attenuation and pathogenesis. In vivo characterization demonstrated that the GFP/DES4 marker virus was attenuated, with a lower level of viraemia, which suggests that this marker virus would be a good backbone for further development of vaccines.
Interestingly, ES4 epitope deletion improved the stability of the GFP insertion in nsp2. The mechanism for tolerating foreign gene insertion or epitope deletion in this region remains to be determined. The nsp2 protein may have size limitations for foreign gene insertion. This result is consistent with previous findings in type 2 viruses where the replacement of a 110 aa region of nsp2 with GFP improved the stability of GFP expression (Kim et al., 2007) . Another interesting observation was the loss of GFP fluorescence in vitro and in vivo although the GFP gene remained intact. Sequence analysis consistently identified the R97C mutation in the GFP protein. The R97C mutation is the same amino acid mutation identified in GFP that was inserted into the nsp2 region of a type 2 virus (Kim et al., 2007) . As indicated by Kim et al. (2007) , R97 plays a key role in the chromophore formation of GFP, which suggests that the chromophore formation may affect nsp2 function. In addition, as cysteine is the amino acid normally involved in forming the disulfide bond in the protein, we speculate that the additional disulfide bond may be required to maintain the correct conformation of nsp2 in order to function. The defined mechanism of these observations remains to be determined. Nevertheless, the GFP protein retained its immunogenicity in vivo and functions as an excellent positive marker for the differentiation between vaccinated and wild-type virus-infected animals.
